Less than six months after a series A fundraise, AI drug developer Chai Discovery has brewed up a $130 million series B to ...

As 2025 closes out, a pair of autoimmune biotechs have eked out separate deals with Big Pharma before year-end, each with a sizeable potential payout down the line. | Seattle’s Adaptive ...

Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease ...

Ringside’s phase 3 findings reveal the potential varegacestat has to deliver “best-in-class results in a convenient, ...

Philips has claimed the cardiac artificial intelligence developer SpectraWAVE in a bid to expand the capabilities of its real ...

Lumexa Imaging hauled in $462.5 million during its initial public offering, far exceeding the $200 million the outpatient ...

So continues the rocky path for the drug, which Sanofi picked up in its $3.7 billion buyout of Principia Biopharma back in ...

Fresh off a $153 million series E round, Arthrosi Therapeutics is skipping an IPO route and is instead being bought up for a ...

CMS spending on skin substitutes is rising. New policies are an important first step in reform to ensure patient access and ...

Unmatched expertise in patient recruitment and retentionOne of the critical challenges in clinical trials is patient ...

The FDA’s oversight of medical device recalls continues to be plagued by staffing challenges—forcing some activities to be ...

Zealand Pharma may be gearing up for a high-stakes year of obesity readouts, but the Danish biopharma thinks the brain could hold the key to the company’s long-term success. | Zealand Pharma may be ...